3-氨基-6-氯-1H-吲唑 | 16889-21-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 3-氨基-6-氯-1H-吲唑
• 英文名称: 6-chloro-1H-indazol-3-amine
• 英文别名: 3-Amino-6-chlorindazol；3-amino-6-chloro-1H-indazole
• CAS: 16889-21-7
• 化学式: C₇H₆ClN₃
• 分子量: 167.598
• InChiKey: BPTYMRSBTUERSW-UHFFFAOYSA-N

物化性质

• 沸点：
  408.7±25.0 °C(Predicted)
• 密度：
  1.533±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Amino-6-chloro-1h-indazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Amino-6-chloro-1h-indazole
CAS number: 16889-21-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H6ClN3
Molecular weight: 167.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氨基-6-氯-1H-吲唑 以 乙醚 、 焦碳酸二乙酯 为溶剂， 生成 3-amino-6-chloro-indazole-1-carboxylic acid ethyl ester
  参考文献：
  名称：

  3-Aminoindazole-1 and 2-carboxylic acid derivatives

  摘要：

  1-或2-位上带有羧基（较低的烷氧基）、较低的烷基酰胺或二（较低烷基）酰胺基团的3-氨基吲唑，可选地在4、5、6和/或7位上进一步取代，具有镇痛、抗炎和退热作用。这些化合物，其中3-氨基-6-氯吲唑-1-羧酸乙酯是典型的实施例，通过将适当的3-氨基吲唑与碳酸衍生物处理或通过热异构化制备。

  公开号：

  US04051252A1
• 作为产物：
  描述：

  4-氯-2-氟苯腈 在 肼 作用下， 以 异丙醇 为溶剂， 反应 24.0h， 以2.45 g的产率得到3-氨基-6-氯-1H-吲唑
  参考文献：
  名称：

  [EN] INDAZOLE GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF
  [FR] INHIBITEURS D' ATPASE DE TYPE F1F0, À BASE DE GUANIDINE D'INDAZOLE

  摘要：

  这项发明提供了抑制F1F0-ATP酶的吲唑胍类化合物，以及将这些吲唑胍类化合物作为治疗剂用于治疗医学疾病的方法，如免疫紊乱、炎症症状或癌症。

  公开号：

  WO2013185045A1

文献信息

• [EN] ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C<br/>[FR] POLYTHÉRAPIE ANTICANCÉREUSE AVEC UN INHIBITEUR DE N-(1-ACRYLOYL-AZÉTIDIN-3-YL)-2-((1H-INDAZOL-3-YL) AMINO) MÉTHYL)-1 H-IMIDAZOLE-5-CARBOXAMIDE DE KRAS-G12C
  申请人：TAIHO PHARMACEUTICAL CO LTD

  公开号：WO2021215545A1

  公开（公告）日：2021-10-28

  A method of treating cancer comprises administering: (a) a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and (b) a therapeutically effective amount of an additional anti-cancer agent, to a subject in need of such treatment, the compound of Formula (I) being: where X, R1, R2, ring A, L1, L2, L3, and R5 are as defined in this disclosure.

  治疗癌症的方法包括向需要此类治疗的受试者施用：(a) 公式(I)的化合物或其药用可接受的盐的治疗有效量；和(b) 另一种抗癌药物的治疗有效量，其中公式(I)的化合物为：其中X、R1、R2、环A、L1、L2、L3和R5的定义如本公开说明书中所定义。
• [EN] INDAZOLE GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF<br/>[FR] INHIBITEURS D' ATPASE DE TYPE F1F0, À BASE DE GUANIDINE D'INDAZOLE
  申请人：LYCERA CORP

  公开号：WO2013185045A1

  公开（公告）日：2013-12-12

  The invention provides indazole guanidine compounds that inhibit F1F0-ATPase, and methods of using indazole guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

  这项发明提供了抑制F1F0-ATP酶的吲唑胍类化合物，以及将这些吲唑胍类化合物作为治疗剂用于治疗医学疾病的方法，如免疫紊乱、炎症症状或癌症。
• 2-吡啶取代脲结构小分子化合物及其合成和应用
  申请人：中国科学院上海药物研究所

  公开号：CN110818683B

  公开（公告）日：2023-04-14

  本发明涉及2‑吡啶取代脲结构小分子化合物及其合成和应用。具体地，本发明公开了式(I)所述的化合物，其对映异构体、非对映异构体、外消旋体或其混合物，或其药学上可接受的盐、水合物及溶剂合物及其制备方法和在制备ASK1小分子抑制剂，或预防和/或治疗与ASK1相关疾病，尤其是肝脏疾病、肺部疾病、心血管疾病、肾脏疾病和代谢性疾病的药物中的用途。
• Synthesis of Purine Analogues: Photocatalyst-Free Visible-Light-Enhanced Annulation Approach to Pyrazolo[1,5-<i>a</i>][1,3,5]triazine-2,4-diamines
  作者：Wei Guo、Zhen Xie、Liuhuan Cai、Gongping Liu、Ling Deng、Weijie Mei、Xiaoying Zou、Yumei Zhong、Xiaoya Zhuo、Lvyin Zheng、Xiaolin Fan

  DOI：10.1021/acs.joc.1c00783

  日期：2021.6.18

  pyrazolo[1,5-a][1,3,5]triazine-2,4-diamines via the formation of electron donor–acceptor (EDA) complexes is reported. The in situ generated pyrazolthiourea intermediates from 1H-pyrazol-3-amines and isothiocyanates undergo formal [4 + 2] annulation with 1,1,3,3-tetramethylguanidines (TMG) to deliver the corresponding products involved in three C–N bond formations in a one-pot protocol. The formation of EDA

  通过形成电子供体 - 受体（EDA）复合物合成吡唑并[1,5- a ][1,3,5]三嗪-2,4-二胺的一种新的无光催化剂可见光增强策略是报道。在原位从1个产生pyrazolthiourea中间体ħ吡唑-3-胺和异硫氰酸酯进行正式[4 + 2]环与1,1,3,3- tetramethylguanidines（TMG）以提供所涉及的三个C-N键的相应的产品在一锅协议中的形成。由吡唑硫脲和 TMG 形成 EDA 复合物通过紫外-可见光谱和1核磁共振实验。此外，这种温和的反应在没有任何外部过渡金属、氧化剂、碱和配体的情况下进行。这种合成嘌呤类似物吡唑并[1,5- a ][1,3,5]三嗪-2,4-二胺的有效方法在药物研发领域提供了潜在的合成应用。
• Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof
  申请人：——

  公开号：US20040014802A1

  公开（公告）日：2004-01-22

  The present invention relates to the novel indazole derivatives of general formula (I): 1 in which: R is either O, S or NH; R3 is an alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, aryl, heterocycle, cycloalkyl, alkenyl, etc. radical; these radicals being optionally substituted with one or more substituents; R4, R5, R6 and R7 are chosen, independently of each other, from the following radicals: hydrogen, halogen, CN, NO 2 , NH 2 , OH, COOH, C(O)OR8, —O—C(O)R8, NR8R9, NHC(O)R8, C(O)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(O)R8, SO 2 R8, NHSO 2 R8, SO 2 NR8R9, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, cycloalkyl, alkenyl, etc.; these radicals being optionally substituted with one or more substituents.

  本发明涉及一般式(I)的新型吲唑衍生物： 1 其中：R为O、S或NH；R3为烷基、芳基、芳基烷基、杂芳基、杂芳基烷基、芳基、杂环、环烷基、烯基等基团；这些基团可以选择性地被一个或多个取代基取代；R4、R5、R6和R7分别选择自以下基团：氢、卤素、CN、NO 2 、NH 2 、OH、COOH、C(O)OR8、—O—C(O)R8、NR8R9、NHC(O)R8、C(O)NR8R9、NHC(S)R8、C(S)NR8R9、SR8、S(O)R8、SO 2 R8、NHSO 2 R8、SO 2 NR8R9、三氟甲基、三氟甲氧基、烷基、烷氧基、芳基、芳基烷基、杂芳基、杂芳基烷基、杂环、环烷基、烯基等；这些基团可以选择性地被一个或多个取代基取代。